spectrin repeat containing nuclear envelope family member 3Genealiases: C14orf139 · C14orf49 · KASH3 · LINC00341 · NCRNA00341 · NET53
Q-omics provides the consensus-scored SYNE3 profile across patient tissues and cancer cell-line models. SYNE3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SYNE3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SYNE3 RNA expression shows 22,314 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BLCA, and LSCC as cancer lineages where SYNE3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNE3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNE3 survival associations across molecular data types. SYNE3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNE3 RNA expression–survival associations across cancer types. High SYNE3 expression shows unfavorable associations in KIRP and LUSC, but favorable associations in HNSC, KIRC, LUAD and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SYNE3 RNA expression.
This table summarizes SYNE3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SYNE3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNE3 shows lower tumor expression in BLCA, COAD, LUAD, KIRP and THCA and higher tumor expression in KIRC. The BLCA box plot shows higher SYNE3 RNA expression in normal versus tumor tissue (log2 FC = −0.869, t-test p < 0.001).
This table shows molecular features associated with SYNE3 in patient tissues and cancer cell lines. In patient samples, SYNE3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNE3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
